Abstract
This chapter discusses the use of serum phosphohexose isomerase (PHI) and carcinoembryonic antigen (CEA) determinations in clinical management of breast cancer. It is suggested that PHI and CEA could correlate with the involvement of axillary lymph nodes and the presence (or absence) of distant metastases. Breast cancer patients have significantly higher levels than benign disease cases and controls. It allows the suggestion that the finding of abnormal levels of one or both tests may indicate the presence of malignancy. In locoregional disease preoperative levels may have prognostic significance, because they usually correlated with tumor mass, lymph node involvement of axilla and the rate of relapses. Serial determinations of one of these tests might be of value in the follow up of patients with disseminated disease as the levels of PHI and CEA parallel the clinical course of the disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
